Navigation Links
Gene therapy study shows safety and statistically significant improvement in Parkinson's disease

chairman of the Neurologix Scientific Advisory Board and recipient of the 2000 Nobel Prize for Physiology or Medicine for his work related to how brain cells communicate. “The significant and sustained improvements in clinical symptoms following treatment of only one side of the brain are impressive. Moreover, the PET results offer an important window into the function of the living brain in these patients, which supports a normalization of brain activity specific to the treated hemisphere.”

The study used an adeno-associated virus (AAV) vector to deliver an inhibitory gene (glutamic acid decarboxylase or “GAD”) to the subthalmic nucleus (STN) of the brain. In Parkinson’s disease, STN activity is abnormally increased, largely due to a deficit in GABA (gamma-aminobutyric acid), the major inhibitory neurotransmitter in the brain. Increasing GAD causes more GABA to be synthesized, thus helping to calm the STN over-activity. The value of this strategy has been demonstrated in previous human studies where reducing STN activity by either electrical stimulation or lesioning can help ameliorate the symptoms of advanced Parkinson’s disease.

The Phase 1 study was not specifically designed to assess efficacy. Nonetheless, the researchers reported the clinical outcomes to be very encouraging, with treated patients showing significant improvement in both the “on” and “off” states of their illness (the time periods in which they achieve or do not realize benefit from drug therapy) beginning at three months following surgery and continuing through the end of the study. These improvements occurred predominantly on the side of the body corresponding to the side of the brain receiving treatment. Moreover, the absence of change at the earliest time point following treatment suggests that the improvement was not likely due to the surgical lesioning of the targeted brain region, as surgical approaches typically give rise to immediate, short-lasting benefit around the
'"/>

Source:JKureczka@comcast.net


Page: 1 2 3 4

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... of the greatest mysteries of modern coral reefs is how ... has long existed in the record of coral evolution. ... in sea level and changes in the Earth,s climate between ... many "old" corals went extinct, and the modern reef corals ...
... the University of Alberta have made a discovery that may ... cow disease, adapt in order to spread between various types ... discovered that a miniscule change in the prions, makeup appears ... mimic and recreate new strains with which it comes into ...
... For hundreds of years, naturalists and scientists have ... differences. But now, new genetic techniques are revealing ... visible differences. In a just-published study, evolutionary ... the American Museum of Natural History (AMNH) combine ...
Cached Biology News:University of Miami geologists to address the mystery of an evolution gap in reef corals 2Discovery may explain how prion diseases spread between different types of animals 2Researchers develop tools for discovering new species 2Researchers develop tools for discovering new species 3
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
(Date:8/26/2015)... San Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... three major conferences to develop new business relationships with local sponsors in southern California. ... services to facilitate their drug development processes and regulatory pathways., , ...
(Date:8/25/2015)... Aug. 25, 2015 Human Longevity, Inc. (HLI), the ... has joined the company as Chief Operating Officer. Winham, ... operations and technical experience, will report directly to HLI,s CEO, ... this new role as COO, Winham will be responsible for ... well as all facility operations. HLI currently has three locations ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2
... VIRGINIA BEACH, Va., Oct. 7, 2008 AMERIGROUP,Corporation ... will report its earnings,for the third quarter ended ... October 22, 2008. At 8:30 a.m. Eastern Time ... a conference call and webcast,to discuss earnings and ...
... of Lives, GERMANTOWN, Md., Oct. 7 ... development of medical,countermeasures for biodefense and emerging infectious ... for advanced development of a,vaccine to protect against ... Allergy and Infectious Diseases (NIAID), part of the ...
... Maryland, October 7 Orthocrat Ltd., announced,today ... purchased,TraumaCad(TM), a web-based pre-operative planning and digital ... used X-ray films and acetate,overlays to determine ... for,joint-replacement surgery. With the adoption of digital ...
Cached Biology Technology:AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 23 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 3George Washington University Hospital Purchases Orthocrat's TraumaCad(TM) for Orthopedic Preoperative Planning 2George Washington University Hospital Purchases Orthocrat's TraumaCad(TM) for Orthopedic Preoperative Planning 3
...
... pAcGHLT-A,B,C Baculovirus ... Set,pAcGHLT-XylE Baculovirus ... Powder,Thrombin Dilution ... Cocktail,Insect Cell ...
...
... Plus accurately and conveniently controls the temperature at ... different temperature levels up to 99 C*, with ... as low as 5 C. The thermoblocks for ... tubes, and microplates enable a high degree of ...
Biology Products: